CHENG Sze Lok AlfredAssociate Professor

Telephone:  39439842

Email:  This email address is being protected from spambots. You need JavaScript enabled to view it.


 Rm 405A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK


  1. Epigenetic regulation of tumor cells and tumor microenvironment
  2. Transcriptional enhancers in carcinogenesis
  3. Molecular mechanisms underlying male predominance of liver cancer
  1. Sun, H., Yang, W., Tian, Y., Zeng, X., Zhou, J., Mok, M.T., Tang, W., Feng, Y., Xu, L., Chan, A.W., Tong, J.H., Cheung, Y.S., Lai, P.B., Wang, H.K., Tsang, S.W., Chow, K.L., Hu, M., Liu, R., Huang, L., Yang, B., Yang, P., To, K.F., Sung, J.J., Wong, G.L.*, Wong, V.W.*, Cheng, A.S.L.* (2018). An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nature Communications, in press.
  2. Lee, Y., Mok, M.T.S., Kang, W., Yang, W., Tang, W., Wu, F., Xu, L., Yan, M., Yu, Z., Lee, S.D., Tong, J.H., Cheung, Y.S., Lai, P.B., Yu, D.Y., Wang, Q., Wong, G.L., Chan, A.M., Yip, K.Y., To, K.F., Cheng, A.S.L.* (2018). Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis. Nucleic Acids Research, 46, 8832-8847.
  3. Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A.W.H., Tong, J.H., Wong, J., Chong, C.C.N., Lai, P.B.S., Wang, H.K., Tsang, S.W. Goodwin, T., Liu, R., Huang, L., Chen, Z., Sung, J.J., Chow, K.L., To, K.F., Cheng, A.S.L.* (2018). Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut, 67,931-944.
  4. Song, H., Yu, Z., Sun, X., Feng, J., Yu, Q., Khan, H., Zhu, X., Huang, L., Li, M., Mok, M.T.S., Cheng, A.S.L.*, Gao, Y.,* Feng, H.* (2018). Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling. EBioMedicine, 35,155-166.
  5. Mok, M.T., Zhou, J., Tang, W., Zeng, X., Oliver, A.W., Ward, S.E., Cheng, A.S.L.* (2018). CCRK is a novel signalling hub exploitable in cancer immunotherapy. Pharmacology & Therapeutics, 186, 138-151.
  6. Cao, Q., Anyansi, C., Hu, X., Xu, L., Xiong, L., Tang, W., Mok, M.T.S., Cheng, C., Fan, X., Gerstein, M., Cheng, A.S.L., Yip, KY. (2017). Reconstruction of enhancer-target networks in 935 samples of human primary cells, tissues and cell lines. Nature Genetics, 49,1428-1436.
  7. Zhang, B., Zhang, Y., Zou, X., Chan, A.W., Zhang, R., Lee, T.K., Liu, H., Lau, E.Y., Ho, N.P., Lai, P.B., Cheung, Y.S., To, K.F., Wong, H.K., Choy, K.W., Keng, V.W., Chow, L.M., Chan, K.K., Cheng, A.S.L., Ko, B.C. (2017). The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. Journal of Pathology, 243,418-430.
  8. Zhou, M., Mok, M.T., Sun, H., Chan, A.W., Huang, Y., Cheng, A.S.L.*, Xu, G.* (2017). The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. Oncogene, 36, 4135-4149.
  9. Liu, M., Zhou, J., Chen, Z., Cheng, A.S.L.* (2017). Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. Journal of Pathology, 241, 10-24.
  10. Cheung, O.K., Cheng, A.S.L.* (2016) Gender Differences in Adipocyte Metabolism and Liver Cancer Progression. Frontiers in Genetics, 7, 168.
  11. Wu, W.K.*, Yu, J., Chan, M.T., To, K.F., Cheng, A.S.L. (2016). Combinatorial epigenetic deregulation by Helicobacter pylori and Epstein-Barr virus infections in gastric tumorigenesis, Journal of Pathology, 239(3), 245-249.
  12. Bai, A.H., Wu, W.K., Xu, L., Wong S.H., Go, M.Y., Chan, A.W., Harbord, M., Zhang, S., Chen, M., Wu, J.C., Chan, M.W., Chan, M.T., Chan, F.K., Sung, J.J., Yu, J., Cheng, A.S.L.*, Ng S.C.* (2016). Dysregulated lysine acetyltransferase 2B promotes inflammatory bowel disease pathogenesis through transcriptional repression of interleukin-10.  Journal of Crohn's and Colitis, 10(6), 726-734 (*Co-corresponding author).
  13. Tsang, D.P., Wu, W.K., Kang, W., Lee Y.Y., Wu, F., Yu, Z., Xiong, L., Chan, A.W., Tong, J.H., Yang, W., Li, M.S., Lau, S.S., Li, X., Lee S.D., Yang, Y., Lai, P.B., Yu, D.Y., Xu, G., Lo, K.W., Chan, M.T., Wang, H., Lee, T.L., Yu, J., Wong, N, Yip, K.Y., To, K.F., Cheng A.S.L.* (2016). Yin Yang 1-mediated epigenetic silencing of tumor-suppressive microRANs activates nuclear factor-kB in hepatocellular carcinoma.  Journal of Pathology, 238(5), 651-664.
  14. Yang, W., Mok, M.T., Li, M.S., Kang, W., Wang H., Chan, A.W., Chou, J.L., Chen J., Ng, E.K.W., To, K.F., Yu, J., Chan, M.W.Y., Chan, F.K.L., Sung, J.J.Y., Cheng, A.S.L. (2016). Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development.  Oncogene, 35(16), 2133-2144. (*Corresponding author).
  15. Tian, Y., Wong, V.W., Wong, G.L., Yang, W., Sun, H., Shen, J., Tong, J.H., Go, M.Y., Cheung, Y.S., Lai, P.B., Zhou, M., Xu, G., Huang, T.H., Yu, J., To, K.F., Cheng, A.S.L.*, Chan, H.L.* (2015). Histone deacetylase HDAC8 promotes insulin resistance and ß-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Research, 75(22), 4803-4816. (*Co-corresponding author).
  16. Zhu, R., Mok, M.T., Kang, W., Lau, S.S., Yip, W.K., Chen, Y., Lai, P.B., Wong, V.W., To, K.F., Sung, J.J., Cheng, A.S.L.*, Chan, H.L.* (2015). Truncated HBx-dependent silencing of GAS2 promotes hepatocarcinogenesis through deregulation of cell, senescence and p53-mediated apoptosis.  Journal of Pathology, 237(1), 38-49. (*Co-corresponding author)
  17. Mok, M.T.S., Cheng, A.S.L.* (2015). CUL4B: a novel epigenetic driver in Wnt/ß-catenin-dependent hepatocarcinogenesis. Journal of Pathology, 236(1), 1-4.  (*Corresponding author)
  18. Shen, J., Xiao, Z., Wu, W.K.*, Wang, M.H., To, K.F., Chen, Y., Yang, W., Li, M.S., Shin, V.V., Tong, J.H., Kang, W., Zhang, L., Li, M., Wang, L., Lu, L., Chan, R.L., Wong, S.H., Yu, J., Chan, M.T., Chan, F.K., Sung, J.J., Cheng, A.S.L.*, Cho, C.H. (2015). Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis. Cancer Research, 75(4), 754-765 (*Co-corresponding author)
  19. Feng, H., Yu, Z., Tian, Y., Lee, Y.Y., Li, M.S., Go, M.Y., Cheung, Y.S., Lai, P.B., Chan, A.M., To, K.F., Chan, H.L., Sung, J.J., Cheng, A.S.L.  (2015). A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.  Journal of Hepatology, 62(5), 1100-1111. (*Corresponding author)
  20. Yu, Z., Gao, Y.Q., Feng, H., Lee, Y.Y., Li, M.S., Tian, Y., Go, M.Y., Yu, D.Y., Cheung, Y.S., Lai P.B., Yu, J., Wong, V.W., Sung, J.J., Chan, H.L.*, Cheng, A.S.L. (2014). Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis.  Gut, 63(11), 1793-1804.  (*Co-corresponding author)
  21. Tian, Y., Wong, V.W., Chan, H.L., Cheng, A.S.L.* (2013). Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Seminar in Cancer Biology, 23(6 Pt B):471-482. (*Corresponding author)
  22. Cheng, A.S.L.*, Li, M.S., Kang, W., Cheng, V.Y., Chou, J.L., Lau, S.S., Go, M.Y., Lee, C.C., Ling, T.K., Ng, E.K., Yu, J., Huang, T.H., To, K.F., Chan, M.W., Sung, J.J., Chan, F.K.* (2013). Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology, 144(1):122-133.e9; (*Co-corresponding author) (Coverage/Editorial: Gastroenterology 2013; 144, 22-25; F1000 Faculty
  23. Ren, S.X., Cheng, A.S.L.#, To, K.F., Tong, J.H., Li, M.S., Shen, J., Wong, C.C., Zhang, L., Chan, R.L., Wang, X.J., Ng, S.S., Chiu, L.C., Marquez, V.E., Gallo, R., Chan, F.K., Yu, J., Sung, J.J., Wu, W.K., Cho, C.H. (2012). Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Research, 72(24), 6512-6523. (#Co-first author)
  24. Feng, H., Cheng, A.S.L.*, Tsang, D.P., Li, M.S., Go, M.Y., Cheung, Y.S., Ng, S.S., Lin, M.C., To, K.F., Yu, J., Lai, P.B., Sung, J.J.* (2011). Cell cycle–related kinase is a direct androgen receptor-regulated gene driving ß-catenin/T-cell factor-dependent hepatocarcinogenesis. Journal of Clinical Investigation, 121(8), 3159-3175 (*Co-corresponding author) (Coverage/Editorial: Nature China 2011 doi:10.1038/nchina.2011.58; Hepatology 2012, 55,970-973.)
  25. Cheng, A.S.L.*, Lau, S.S., Chen, Y., Kondo, Y., Li, M.S., Feng, H., Ching, A.K., Cheung, P.K., Wong, K.H., Jin, H., Choy, R., Yu, J., To, K.F., Wong, N., Huang, T.H., Sung, J.J. (2011). EZH2-mediated concordant repression of Wnt antagonists promotes ß-catenin-dependent hepatocarcinogenesis. Cancer Research, 71(11), 4028-4039. (*Corresponding author)
  26. Tsang, D.P. and Cheng, A.S.L. (2011). Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. Journal of Gastroenterology and Hepatology, 26(1), 19-27. (*Correseponding author)
  27. Wang, H., Garzon R., Sun, H., Ladner, K.J. Singh, R., Dahlman, J., Cheng, A.S.L., Hall, B.M., Qualman, S.J., Chandler, D.S., Croce, C.M., Guttridge, D.C. (2008) NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell, 14(5), 369-381.
  28. Kondo, Y., Shen, L., Cheng, A.S.L., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, K., Huang, T.H.M., Issa, J.P. (2008). Gene silencing in cancer by histone H3 lysine 27 tri-methylation independent of promoter DNA methylation, Nature Genetics, 40(6),741-750.
  29. Cheng, A.S.L., Culhane, A.C., Chan, M.W., Venkataramu, C.R., Ehrich, M., Nasir, A., Rodriguez, B.A., Liu, J., Yan, P.S., Quackenbush, J., Nephew, K.P., Yeatman, T.J., Huang, T.H. (2008). Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome, Cancer Research, 68(6),1786-1796
  30. Cheng, A.S.L., Jin, V.X., Fan, M.Y., Smith, L.T., Liyanarachchi, S., Yan, P.S., Leu, Y.W., Chan, M.W.Y., Plass, C., Nephew, K.P., Davuluri, R.V., Huang, T.H.M. (2006). Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor α-responsive promoters, Molecular Cell, 21(3), 393-404.